Results 11 to 20 of about 947,345 (358)

Src Dependent Pancreatic Acinar Injury Can Be Initiated Independent of an Increase in Cytosolic Calcium [PDF]

, 2013
Several deleterious intra-acinar phenomena are simultaneously triggered on initiating acute pancreatitis. These culminate in acinar injury or inflammatory mediator generation in vitro and parenchymal damage in vivo. Supraphysiologic caerulein is one such
A Gnoni, A Pace, A Sharma, AJ Hietaranta, AK Saluja, AK Saluja, AS Gukovskaya, B Han, B Han, B Hofbauer, B Kruger, C Schafer, Catherine J. Baty, CH Kubisch, Chandra Durgampudi, Chathur Acharya, DN Criddle, Donna B. Stolz, EC Thrower, EM Parker, F Gorelick, F Mooren, F Nozu, G Lynch, H Weber, HK Baumgartner, I Gukovsky, I Gukovsky, I Samuel, JA Tapia, JA Williams, Jenny Karlsson, JV Gerasimenko, KA Muili, Krutika Patel, L Fischer, L Orlichenko, Lidiya Orlichenko, LJ Christopher, LJ Lombardo, LS Orlichenko, M Sendler, MS O'Konski, OA Mareninova, OH Petersen, Pawan Noel, PC Redondo, Rachel Cline, Ram Narayan Trivedi, RD Duan, RR Torgerson, RR Torgerson, S Kawabata, S Navina, Sarah Navina, SD Waterford, SG Weller, SJ Pandol, Sohail Z. Husain, Stuart E. Dryer, SZ Husain, SZ Husain, T Eley, T Grady, T Grady, V Sancho, Vijay P. Singh, Vivek Mishra, VP Singh, VP Singh, VP Singh, VP Singh, Y Tsunoda   +72 more
core   +10 more sources

An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report

Journal of Medical Case Reports, 2020
Background Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is selective for both epidermal growth factor receptor tyrosine kinase inhibitor–sensitizing and T790M resistance mutations.
Shinichi Miyazaki, Yasumasa Kuno, Shunsaku Hayai, Ryo Teramachi, Ryo Yamashita, Yusuke Saito, Kosuke Higuchi, Yoshiharu Nara, Takuya Ikeda   +8 more
doaj   +1 more source

Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors

JTO Clinical and Research Reports, 2023
Introduction: EGFR tyrosine kinase inhibitors are standard therapeutic agents for patients with advanced NSCLC harboring EGFR mutations. Nevertheless, some patients exhibit primary resistance to EGFR tyrosine kinase inhibitors in the first-line treatment
Ryota Nakamura, MD, Hiroyuki Fujii, MD, Tadaaki Yamada, MD, PhD, Yohei Matsui, MD, Takeshi Yaoi, MS, Mizuki Honda, MD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Akihiro Yoshimura, MD, PhD, Kenji Morimoto, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Eiichi Konishi, MD, PhD, Kyoko Itoh, MD, PhD, Koichi Takayama, MD, PhD   +15 more
doaj   +1 more source

Construction of a circRNA-miRNA-mRNA Regulated Pathway Involved in EGFR-TKI Lung Adenocarcinoma Resistance

Technology in Cancer Research & Treatment, 2021
Objectives: Epidermal growth factor receptor-tyrosine kinase inhibitors are widely used for lung epidermal growth factor receptor-positive lung adenocarcinomas, but acquired resistance is inevitable.
Chenyue Dai MM, Bing Liu MD, Shaolei Li PhD, Yang Hong PhD, Jiahui Si PhD, Ying Xiong MSc, Nan Wu MD, Yuanyuan Ma PhD   +7 more
doaj   +1 more source

Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Frontiers in Oncology, 2021
Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis.
Ting-Ting Yang, Ting-Ting Yang, Ting-Ting Yang, Wei-Hao Chen, Wei-Hao Chen, Wei-Hao Chen, Yan-Min Zhao, Yan-Min Zhao, Yan-Min Zhao, Hua-Rui Fu, Hua-Rui Fu, Hua-Rui Fu, He Huang, He Huang, He Huang, Ji-Min Shi, Ji-Min Shi, Ji-Min Shi   +17 more
doaj   +1 more source

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets. [PDF]

, 2017
BackgroundLiposarcoma, the most common soft tissue tumor, is understudied cancer, and limited progress has been made in the treatment of metastatic disease.
Doan, Ngan B, Forscher, Charles, Garg, Manoj, Kanojia, Deepika, Koeffler, H Phillip, Luty, Samuel B, M T, Anand, Martinez, Jacqueline, Said, Jonathan W, Tyner, Jeffrey W   +9 more
core   +2 more sources

Control of renal cell carcinoma brain metastases with cabozantinib following progression on immune checkpoint inhibitor therapy

Current Problems in Cancer: Case Reports, 2021
Patients with metastatic renal cell carcinoma are often affected by metastases to the brain that result in significant complications as well as limitations in clinical trial participation.
Cierra Hong, Kristen A. Batich, Garland Almquist, Luis Villa, Daniel J. George, Tian Zhang   +5 more
doaj   +1 more source

EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5 [PDF]

, 2013
Background: Tks5/FISH is a scaffold protein comprising of five SH3 domains and one PX domain. Tks5 is a substrate of the tyrosine kinase Src and is required for the organization of podosomes/invadopodia implicated in invasion of tumor cells.
Buday, László, Bőgel, Gábor, Fekete, Anna, Geiszt, Miklós, Pesti, Szabolcs, Péterfi, Zalán   +5 more
core   +1 more source

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

Journal of Biological Chemistry, 1996
Here, we have studied the activity of a novel protein-tyrosine kinase inhibitor that is selective for the Src family of tyrosine kinases. We have focused our study on the effects of this compound on T cell receptor-induced T cell activation, a process ...
J. Hanke, J. Gardner, R. L. Dow, P. Changelian, W. Brissette, E. J. Weringer, B. Pollok, P. Connelly   +7 more
semanticscholar   +1 more source

Novel Multitarget Therapies for Lung Cancer and Respiratory Disease

Molecules, 2020
In recent years, multitarget drugs for neurological diseases such as Alzheimer’s disease have been developed and well researched. Many studies have revealed that multitarget drugs are also useful for lung cancer and respiratory diseases.
Masako Yumura, Tatsuya Nagano, Yoshihiro Nishimura   +2 more
doaj   +1 more source